The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: A comparison with amphetamine

Pharmacology Biochemistry and Behavior

Volumn 62, Issue 3, 1999, Pages 403-408

  Lin, Hui Qiang ^a   Burden, Peter M ^a   Christie, Macdonald J ^a   Johnston, Graham A R ^a  

^a University of Sydney   (Australia)

Author keywords

Amphetamine; Anxiety; Elevated plus maze; MDMA; Mice

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; DIAZEPAM;

ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHETAMINE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DIAZEPAM; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MALE; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE;

EID: 0033012662     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00191-9     Document Type: Article

References (39)

1. Andrews N., File S.E., Fernandes C., Gonzalez L.E., Barnes N.M. Evidence that the median raphe nucleus-dorsal hippocampal pathway mediates diazepam withdrawal-induced anxiety. Psychopharmacology (Berlin). 130:1997;228-234.
2. Battaglia G., Zaczek R., de Souza E.B. MDMA effects in brain. Pharmacologic profile and evidence of neurotoxicity from neurochemical and autoradiographic studies Peroutka S.J. Ecstasy. The clinical, pharmacological and neurotoxicological effects of the drug MDMA:1990;171-199 Kluwer Academic Publishers, Boston.
3. Bird M.P., Svendsen C.N., Knapp C., Hrbek C.C., Bird E.D., Kornetsky C. Evidence for dopaminergic but not serotonergic mediation of the threshold lowering effects of MDMA on reward brain stimulation. Soc. Neurosci. Abstr. 13:1987;1323.
4. Callaway C.W., Wing L.L., Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J. Pharmacol. Exp. Ther. 254:1990;456-464.
5. Cohen R.S. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;1137-1145.
6. Dawson G.R., Crawford S.P., Collinson N., Iversen S.D., Tricklebank M.D. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology (Berlin). 118:1995;316-323.
7. File S.E., Hyde J.R. A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilizers and of stimulants. Pharmacol. Biochem. Behav. 11:1979;65-69.
8. Fitzgerald J.L., Reid J.J. Interactions of methylenedioxymethamphetamine with nonoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch. Pharmacol. 347:1993;313-323.
9. Glennon R.A., Little P.J., Rosecrans J.A., Yousif M. The effect of MDMA ("Ecstasy") and its optical isomers on schedule-controlled responding in mice. Pharmacol. Biochem. Behav. 26:1987;425-426.
10. Gold L.H., Hubner C.B., Koob G.F. A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology (Berlin). 99:1989;40-47.
11. Gold L.H., Koob G.F. Methysergide potentiates the hyperactivity produced by MDMA in rats. Pharmacol. Biochem. Behav. 29:1988;645-648.
12. Greer G., Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J. Psychoactive Drugs. 18:1986;319-327.
13. Hall W., Hando J., Darke S., Ross J. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction. 91:1996;81-87.
14. Hofer M.A. Multiple regulators of ultrasonic vocalization in the infant rat. Psychoneuroendocrinology. 21:1996;203-217.
15. Howell D.C. Statistical methods for psychology. 1997;Duxbury Press, Belmont.
16. Lamb R.J., Griffiths R.R. Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology (Berlin). 91:1987;268-272.
17. Lapin I.P. Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol. Pharmacol. Biochem. Behav. 44:1993;241-243.
18. Liester M.B., Grob C.S., Bravo G.L., Walsh R.N. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J. Nerv. Ment. Dis. 180:1992;345-352.
19. Lin H.Q., Atrens D.M., Christie M.J., Jackson D.M., McGregor I.S. Comparison of conditioned taste aversions produced by MDMA and d-amphetamine. Pharmacol. Biochem. Behav. 46:1993;153-156.
20. Lin H.Q., Jackson D.M., Atrens D.M., Christie M.J., McGregor I.S. Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. Brain Res. 744:1997;351-357.
21. Lin H.Q., McGregor I.S., Atrens D.M., Christie M.J., Jackson D.M. Contrasting effects of dopaminergic blockade on MDMA and d-amphetamine conditioned taste aversions. Pharmacol. Biochem. Behav. 47:1994;369-374.
22. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berlin). 92:1987;180-185.
23. Miczek K.A., Haney M. Psychomotor stimulant effects of d-amphetamine, MDMA and PCP. Aggressive and schedule-controlled behavior in mice Psychopharmacology (Berlin). 115:1994;358-365.
24. Nader M.A., Hoffmann S.M., Barrett J.E. Behavioral effects of (±) 3,4-methylenedioxyamphetamine (MDA) and (±) 3,4-methylenedioxymethamphetamine (MDMA) in the pigeon. Interactions with nonadrenergic and serotonergic systems Psychopharmacology (Berlin). 98:1989;183-188.
25. Nichols D.E., Oberlender R. Structure-activity relationships of MDMA and related compounds. A new class of psychoactive agents Peroutka S.J. Ecstasy. The clinical, pharmacological and neurotoxicological effects of the drug MDMA:1990;105-132 Kluwer Academic Publishers, Boston.
26. Oberlender R., Nichols D.E. Drug discrimination studies with MDMA and amphetamine. Psychopharmacology (Berlin). 95:1988;71-76.
27. Paulus M.P., Geyer M.A. A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology (Berlin). 104:1991;6-16.
28. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
29. Peroutka S.J. Recreational use of MDMA. Peroutka S.J. Ecstasy. The clinical, pharmacological and neurotoxicological effects of the drug MDMA:1990;53-62 Kluwer Academic Publishers, Boston.
30. Peroutka, S. J.: Preface. In: Peroutka, S. J., ed. Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA.Boston: Kluwer Academic Publishers; 1990: XI-XIV.
31. Robbins T., Iversen S.D. A dissociation of the effects of d-amphetamine on locomotor activity and exploration in rats. Psychopharmacologia. 28:1973;155-164.
32. Rodgers R.J., Cutler M.G., Jackson J.E. Behavioral effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Pharmacol. Biochem. Behav. 57:1997;127-136.
33. Schechter M.D. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Biochem. Behav. 31:1988;817-824.
34. Schechter M.D. Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination. Pharmacol. Biochem. Behav. 38:1991;539-544.
35. Schifano F. Chronic atypical psychosis associated with MDMA ("ecstasy") abuse. Lancet. 338:1991;1335.
36. Simon P., Panissaud C., Costentin J. Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol. Biochem. Behav. 45:1993;685-690.
37. Szuster R.R., Pontius E.B., Campos P.E. Marijuana sensitivity and panic anxiety. J. Clin. Psychiatry. 49:1988;427-429.
38. Williamson S., Gossop M., Powis B., Griffiths P., Fountain J., Strang J. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol. Depend. 44:1997;87-94.
39. Winslow J.T., Insel T.R. Serotonergic modulation of rat pup ultrasonic vocal development. Studies with 3,4-methylenedioxy-methamphetamine J. Pharmacol. Exp. Ther. 254:1990;212-220.